Jolanda Paolini

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

Benjamin Solomon, Dong‐Wan Kim, Yi‐Long Wu et al. · Journal of Clinical Oncology · 2018 · 412 citations

Medicine, Oncology, Pharmacology +15

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

Yi‐Long Wu, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2018 · 324 citations · Full text

Medicine, Oncology, Pharmacology +14

Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i> -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Benjamin Solomon, Geoffrey Liu, Enriqueta Felip et al. · Journal of Clinical Oncology · 2024 · 313 citations · Full text

Medicine, Oncology, Pharmacology +13

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Per Eystein Lønning, Jürgen Geisler, Lars Erik Krag et al. · Journal of Clinical Oncology · 2005 · 294 citations · Full text

Medicine, Oncology, Pharmacotherapy +16